Seelos Therapeutics, Inc.

Equities

SEEL

US81577F3073

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 04/06/2024 am IST			5-day change	1st Jan Change
1.11 ^USD	-7.50%		-16.54%	-90.02%

16/05	Seelos Therapeutics, Inc. announced that it expects to receive $1.137029 million in funding	CI
14/05	Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance	MT

Judith Dunn, a Class III Director on the Board of Directors of Seelos Therapeutics, Inc. Notifies to Resign from the Board

September 03, 2021 at 01:31 am IST

On August 27, 2021, Judith Dunn, Ph.D., a Class III Director on the Board of Directors (the “Board”) of Seelos Therapeutics, Inc., notified the Company of her decision to resign from the Board, effective as of September 1, 2021. Dr. Dunn is resigning due to time constraints relating to her other outside professional and business activities, and there are no disagreements between Dr. Dunn and the Company on any matter related to the Company’s operations, policies or practices.

Latest news about Seelos Therapeutics, Inc.

Seelos Therapeutics, Inc. announced that it expects to receive $1.137029 million in funding	16/05	CI
Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance	14/05	MT
Seelos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Seelos Therapeutics, Inc. Announces Resignation of Daniel J. O?Connor from the Board	04/05	CI
Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors	29/04	CI
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	19/03	MT
Seelos Therapeutics' ALS treatment fails in mid-stage study	19/03	RE
Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)	19/03	CI
Seelos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03	CI
Singapore Stocks Open on Monday in Red; IX Biopharma’s Stock Plunge 9% Following Contract Termination	04/03	MT
IX Biopharma’s Subsidiary Issues Termination Notice for Licensing Agreement; Shares Plunge 9%	04/03	MT
Seelos Therapeutics Launches Registered Direct Offering, Concurrent Private Placement	26/01	MT
Seelos Therapeutics, Inc. Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002	22/01	CI
Certain Warrants of Seelos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024.	13/01	CI
Certain Stock Options of Seelos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024.	13/01	CI
Certain Common Stock of Seelos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024.	13/01	CI
Sector Update: Health Care Stocks Gain Premarket Tuesday	19/12	MT
Seelos Therapeutics Files $250 Million Mixed Shelf	19/12	MT
Seelos Therapeutics, Inc.(NasdaqCM:SEEL) dropped from S&P Global BMI Index	18/12	CI
Seelos Therapeutics Insider Bought Shares Worth $100,223, According to a Recent SEC Filing	02/12	MT
Sector Update: Health Care Stocks Mixed Late Afternoon	30/11	MT
Sector Update: Health Care	30/11	MT
Top Midday Decliners	30/11	MT
Top Premarket Decliners	29/11	MT
Seelos Therapeutics Prices Common Stock Offering	29/11	MT

Chart Seelos Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The Company operates under one segment which develops pharmaceutical products. The Company's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The Company's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.

Sector

Biotechnology & Medical Research

Calendar

02/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
SEELOS THERAPEUTICS, INC.	-90.02%	31.29L
VERTEX PHARMACEUTICALS INCORPORATED	+15.55%	12TCr
REGENERON PHARMACEUTICALS, INC.	+12.66%	11TCr
BIONTECH SE	-2.53%	2.43TCr
ARGENX SE	+1.14%	2.2TCr
GENMAB A/S	-9.35%	1.82TCr
WUXI APPTEC CO., LTD.	-42.28%	1.64TCr
BEIGENE, LTD.	-18.92%	1.56TCr
NEUROCRINE BIOSCIENCES, INC.	+6.19%	1.36TCr
SAREPTA THERAPEUTICS, INC.	+28.83%	1.23TCr

Bio Therapeutic Drugs

Seelos Therapeutics, Inc.

Equities

SEEL

US81577F3073

Biotechnology & Medical Research

Judith Dunn, a Class III Director on the Board of Directors of Seelos Therapeutics, Inc. Notifies to Resign from the Board

Latest news about Seelos Therapeutics, Inc.

Chart Seelos Therapeutics, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs